1,4-substituted piperazine derivatives
US8101618B2 · kind B2 · utility
21Cited by
2References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 5, 2006 |
| Grant date | Jan 24, 2012 |
| Priority date | — |
| Expiry date | May 23, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/4858
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound represented by the formula (I):or a pharmaceutically acceptable salt thereof, wherein: This compound has a metabotropic glutamate receptor 1 inhibitory effect, and therefore is useful for the treatment of a brain disorder such as convulsion, acute pain, inflammatory pain, chronic pain, cerebral infraction or transient cerebral ischemic attack, a mental dysfunction such as schizophrenia, and a disease such as anxiety and drug addition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.